01 · Mayamind®
Dementia subtyping
Targets where diagnostic ambiguity is highest—supporting earlier, more specific subtype insight.
Insanity Labs
Precision begins with rigorous measurement—bridging neuroimaging research, clinical validation, and deployable software.
Neuropsychiatric conditions often progress quietly. Our R&D focuses on detecting early, objective markers that traditional assessments miss—then translating those findings into tools clinicians can trust.
01 · Mayamind®
Targets where diagnostic ambiguity is highest—supporting earlier, more specific subtype insight.
02 · Nimixa™
Objective, technician-administered measurement of cognitive task performance—research use only in India.
03 · Clinical studies
Research collaboration across geographies, with a path toward regulated medical use.
Selected peer-reviewed and preprint research underpinning our digital biomarker and dementia subtyping work.
Revankar G.S., Salian A.C., Ozono T., et al.
Read→
Revankar G.S., Furuya K., Mori E., et al.
Read→
Revankar G.S., Ozono T., Suzuki M., et al.
Read→
Hill J., Revankar G., Singh V., Kerber-Folstrom M., Fortuna K.L.
Read→
Revankar G.S., Kajiyama Y., Hattori N., Shimokawa T., Nakano T., Mihara M., Mori E., Mochizuki H.
Read→
Revankar G.S., Kajiyama Y., et al.
Read→
A clear path from clinical question to clinic-ready software—built with evidence and regulation in mind.
Step 1
Partner with clinicians and researchers to identify high-value diagnostic gaps.
Step 2
Design protocols that capture robust, repeatable digital biomarkers.
Step 3
Test against clinical endpoints and real-world care workflows.
Step 4
Ship clinic-ready software with regulatory and operational realities in mind.